Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours

por Hoh, C K, Burris, H A, Bendell, J C, Tarazi, J, Rosbrook, B, Kim, S, Infante, J R, Reid, T R
Publicado 2014

Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies

por Tan, A R, Dowlati, A, Stein, M N, Jones, S F, Infante, J R, Bendell, J, Kane, M P, Levinson, K T, Suttle, A B, Burris III, H A
Publicado 2014

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients...

por Chiorean, E. G., Von Hoff, D. D., Reni, M., Arena, F. P., Infante, J. R., Bathini, V. G., Wood, T. E., Mainwaring, P. N., Muldoon, R. T., Clingan, P. R., Kunzmann, V., Ramanathan, R. K., Tabernero, J., Goldstein, D., McGovern, D., Lu, B., Ko, A.
Publicado 2016